Pure Biologics Stock

Pure Biologics EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Pure Biologics (PUR.WA) as of Aug 9, 2026 is -3.21. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.25 — a change of 156.25% (lower).

EV/EBIT

-3.21

YoY

156.25%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Pure Biologics is 2026 -3.21 . EV/EBIT (Enterprise Value to EBIT) of Pure Biologics was 2025 -1.25 . It decreases by 156.25% lower compared to the previous year.

The Pure Biologics EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2017
0.00 base
Jan 1, 2018
-21.23 base
Jan 1, 2019
-7.27 base
Jan 1, 2020
-8.99 base
Jan 1, 2021
-9.28 base
Jan 1, 2022
-2.71 base
Jan 1, 2023
-1.67 base
Jan 1, 2024
-6.35 base
YEARPRICE-TO-EBIT
2024 -6.35
2023 -1.67
2022 -2.71
2021 -9.28
2020 -8.99
2019 -7.27
2018 -21.23
2017 -
2016 -
Access this data via the Eulerpool API
Get Free API Key

Pure Biologics Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Pure Biologics's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Pure Biologics's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Pure Biologics's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Pure Biologics grows earnings faster than its peers.

Pure Biologics Stock analysis

What does Pure Biologics do? Pure Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pure Biologics stock

EV/EBIT (Enterprise Value to EBIT) of Pure Biologics is -3.21 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Pure Biologics changed from -1.25 to -3.21, representing a 156.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Pure Biologics since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Pure Biologics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Pure Biologics

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Pure Biologics